The global viral hepatitis situation 2006

• **Disease awareness**: extremely low

• **Global priority**: almost none – hepatitis not part of the MDGs or Global Fund

• **Community cohesion**: low – October 1 is Hepatitis Day but only in Europe and Australia

• **World Leadership**: none – out of 8,000 staff at WHO not ONE has ‘hepatitis’ in their job title
Purpose

Creation of the World Hepatitis Alliance

• 2007 Meeting of patient group representatives from around the world
• Decision to establish World Hepatitis Day on May 19th 2008
• Creation of the World Hepatitis Alliance to run it
• 200+ members in 80 countries
• Board Members are elected and unpaid
• The Alliance is a bottom-up organisation, about service, not control

Patients/those at risk
Patient group members
Regional Board Members
President

This is hepatitis...
First ever WHO viral hepatitis resolution

- Refusal of governments to support WHD unless an official day
- Alliance contacts all Ministries of Health to ask for a WHO resolution
- 2009 Afghanistan, Brazil, China, Oman put hepatitis on WHO agenda
- Alliance lobbies for comprehensive resolution
- 2010 WHA63.18 adopted, declaring July 28th as World Hepatitis Day – only the 4th disease-specific official WHO day

Article 3.1 also requested the WHO Director-General to establish in collaboration with Member States the necessary guidelines, strategies, time-bound goals and tools for the surveillance, prevention and control of viral hepatitis;
2010 Resolution WHA63.18

Results at WHO

- Creation of the Global Hepatitis Programme at WHO HQ
- WHO Framework for Global Action
- Guidelines for HCV screening, care and treatment – released April 2014
- Guidelines for HBV screening, care and treatment – released March 2015
- Guidelines for hepatitis surveillance – in development
- Guidelines for HBV and HCV screening – in development

This is hepatitis...
2010 Resolution WHA63.18

Results at country level

- Slow progress
- 47 of 126 MS self-report having a written viral hepatitis strategy
- 23 MS respond to request for strategies but 17 countries actually have them
## Global Burden of Disease

<table>
<thead>
<tr>
<th>Region</th>
<th>Viral Hepatitis</th>
<th>HIV/AIDS</th>
<th>TB</th>
<th>Malaria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASIA PACIFIC TOTAL</strong></td>
<td>1,012,873</td>
<td>304,628</td>
<td>827,567</td>
<td>106,729</td>
</tr>
<tr>
<td><strong>AMERICAS TOTAL</strong></td>
<td>109,025</td>
<td>74,019</td>
<td>25,044</td>
<td>1,268</td>
</tr>
<tr>
<td><strong>EUROPE TOTAL</strong></td>
<td>123,818</td>
<td>82,009</td>
<td>35,803</td>
<td>0</td>
</tr>
<tr>
<td><strong>AFRICA &amp; MIDDLE EAST TOTAL</strong></td>
<td>198,838</td>
<td>1,004,712</td>
<td>307,576</td>
<td>1,061,501</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>1,444,554</td>
<td>1,465,368</td>
<td>1,195,990</td>
<td>1,169,498</td>
</tr>
</tbody>
</table>

This is hepatitis...
WHA66 – hepatitis side meeting

• Feb 2013 Alliance board discusses how to push agenda
• Example of MS working group in ’flu
• Brazil agrees to host side meeting if Alliance organises it
• Brazil and Indonesia co-chair
• Brazil, Indonesia, Mongolia, Egypt and Scotland speak
• Well attended meeting, including new PAHO RD
• Decision not to set up a working group
• Egypt puts hepatitis on 2014 EB agenda
Brazil agrees to lead on new resolution

- Change of personnel at Brazilian HIV and Hepatitis Programme
- World Hepatitis Alliance asked to provide initial draft

Consultation with Argentina, Australia, Brazil, Canada, China, Egypt, France, Myanmar, Nigeria, Pakistan and Senegal

Resolution proposed to the WHO Executive Board (EB) on 20 January 2014

Drafting groups every day
49 Member States (plus Taiwan) speak to support the resolution

<table>
<thead>
<tr>
<th>AFRO</th>
<th>AMRO</th>
<th>EMRO</th>
<th>EURO</th>
<th>SEARO</th>
<th>WPRO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Botswana</td>
<td>Argentina</td>
<td>Afghanistan</td>
<td>France</td>
<td>Bangladesh</td>
<td>Australia</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>Bahamas</td>
<td>Bahrain</td>
<td>Georgia</td>
<td>India</td>
<td>China</td>
</tr>
<tr>
<td>Burundi</td>
<td>Brazil</td>
<td>Egypt</td>
<td>Russia</td>
<td>Indonesia</td>
<td>Japan</td>
</tr>
<tr>
<td>Chad</td>
<td>Canada</td>
<td>Iran</td>
<td>Spain</td>
<td>Maldives</td>
<td>Korea</td>
</tr>
<tr>
<td>Cote d’Ivoire</td>
<td>Guatemala</td>
<td>Iraq</td>
<td>Switzerland</td>
<td>Thailand</td>
<td>Malaysia</td>
</tr>
<tr>
<td>Congo</td>
<td>Panama</td>
<td>Lebanon</td>
<td>Ukraine</td>
<td></td>
<td>Mongolia</td>
</tr>
<tr>
<td>Gambia</td>
<td>Trinidad</td>
<td>Tunisia</td>
<td>UK</td>
<td></td>
<td>Vietnam</td>
</tr>
<tr>
<td>Ghana</td>
<td>US</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kenya</td>
<td>Venezuela</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mauritania</td>
<td>Mauritius</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Somalia</td>
<td>South Africa</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uganda</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2014 Resolution WHA67.6

• (OP) 1. URGES Member States:
  (1) to develop and implement coordinated multisectoral national strategies for preventing, diagnosing, and treating viral hepatitis based on the local epidemiological context;
  (3) to promote the involvement of civil society in all aspects of preventing, diagnosing and treating viral hepatitis;
  (11) to make special provision in policies for equitable access to prevention, diagnosis and treatment for populations affected by viral hepatitis, particularly indigenous people, migrants and vulnerable groups;
  (14) to implement comprehensive hepatitis prevention, diagnosis and treatment programmes for people who inject drugs, including the nine core interventions;
  (16) to review, as appropriate, policies, procedures and practices associated with stigma and discrimination, including the denial of employment, training and education …against people living with and affected by viral hepatitis

• (OP) 2. REQUESTS the WHO’s Director-General:
  (3) in consultation with Member States, to develop a system for regular monitoring and reporting on the progress in viral hepatitis prevention, diagnosis and treatment
  (7) to examine the feasibility of and strategies needed for the elimination of hepatitis B and hepatitis C with a view to potentially setting global targets

This is hepatitis...
2014 Resolution WHA67.6

• Led to the creation of the Global Health Sector Strategy for viral hepatitis

• GHSS has a goal of ‘elimination’ of B and C by 2030

• GHSS 2030 targets:
  - 90% reduction in new cases of B and C (80% C, 95% B)
  - 65% reduction in B and C mortality (from 1.4M to <0.5M)
  - 90% of those with B and C diagnosed
  - 80% of those ‘eligible’ with B and C treated

• GHSS has been widely consulted on

• GHSS has an indicator set (in development)

• GHSS will go to the WHO Executive Board and then the World Health Assembly in 2016
2015-2030 Sustainable Development Goals


- Omission of viral hepatitis due to mortality and morbidity estimates based entirely on HBV and HCV infection (excluding cancer and cirrhosis!!)

- Health a much smaller part of SDGs than MDGs (just one goal 3)

- 3.3 “By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases”.

This is hepatitis...
World Hepatitis Summit

• Need to bring together (physically) all the World Hepatitis Alliance members – over 200

• Need to bring together Ministries of Health specifically around viral hepatitis

• Need for a public health approach to viral hepatitis

• Theme for first Summit – national hepatitis plans – agreed with WHO

• Structure: WHO and WHA plus a host government

• Next Summit: early 2017 Brazil
Glasgow Declaration

The participants of the inaugural World Hepatitis Summit believe it is possible and essential to set as a goal the elimination of both hepatitis B and C as public health concerns. We therefore call upon governments in all jurisdictions to develop and implement comprehensive, funded national hepatitis plans and programmes in partnership with all stakeholders and in line with the World Health Assembly Resolution 67.6 and, in collaboration with the World Health Organization, to define and agree on realistic yet aspirational global targets for prevention, testing, diagnosis, care and treatment.
The global hepatitis community calls for access to life-saving hepatitis drugs

World Hepatitis Summit 2015

More people die each year from hepatitis B and C than from HIV/AIDS, TB or malaria. The single most important reason for this is that they do not have access to life-saving drugs for hepatitis B and hepatitis C. This is a scandal. It is unacceptable.

The undersigned on behalf of the 400 million people living with hepatitis B and C call for the following immediate actions:

1. National governments should take all necessary steps to remove the stigma and discrimination that prevents people coming forward for testing, since the vast majority of those with hepatitis B and C remain undiagnosed

2. National governments should take all necessary steps to put in place adequate infrastructure and to reduce the price of diagnostics sufficiently so that they can afford to screen their at-risk populations and ensure that those testing positive can progress from diagnosis to treatment

3. National governments should take all necessary steps to remove barriers to, and speed up the process of, national registration of anti-viral hepatitis B and C drugs, including the relaxation of requirements for specific national drug trials where good evidence of efficacy and safety already exists.

4. National governments should take all necessary steps to reduce the price of the best anti-viral drugs for hepatitis B and C to the extent that they can afford to massively scale up national treatment programmes but equally so that those forced to pay for the drugs themselves can also afford them. These measures should be decided according to whatever delivers the quickest affordable access to those in need, whether that is the use of TRIPS flexibilities, patent opposition, use of generics or negotiation with pharmaceutical companies.

5. Pharmaceutical companies should take all necessary steps to ensure their drugs are affordable in all countries, whether high, middle or low income. These steps should include:
   - Pricing the drugs so that, as a bare minimum, the best combinations for the optimum treatment duration are always cost-effective in every market based on accepted per capita GDP determinants of cost-effectiveness
   - Making the Intellectual Property of the best drugs available to the Medicines Patent Pool in as many countries as possible

6. Pharmaceutical companies should not:
   - Put in place anti-diversion policies that infringe the confidentiality or human rights of people living with hepatitis B or C
   - Use a dominant market position to prevent people getting access to the best combination of drugs at affordable prices
A Hepatitis Movement

The aim is to create an overarching ‘movement’ that is sufficiently broad that anyone, any group, any organisation, any activity that addresses viral hepatitis can sit within it. It will have the ambition to:

• Strengthen the advocacy voice
• Support single advocates and small groups by making them feel part of a powerful global movement
• Show decision-makers that individual advocacy asks are not isolated but part of a powerful global movement
• Supplement World Hepatitis Day by providing a year-round awareness identity/platform
• Give hepatitis a social identity
• Raise the profile of viral hepatitis, both at the level of policy makers and the general public
THANK YOU